Park National Corp OH Buys New Shares in AstraZeneca PLC $AZNCF

Park National Corp OH bought a new position in AstraZeneca PLC (OTCMKTS:AZNCF) in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 73,331 shares of the company’s stock, valued at approximately $14,462,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Saranac Partners Ltd purchased a new stake in AstraZeneca during the 3rd quarter valued at about $876,000. Mascoma Wealth Management LLC acquired a new position in shares of AstraZeneca in the fourth quarter valued at about $46,000. Valley Wealth Managers Inc. purchased a new position in shares of AstraZeneca in the fourth quarter worth about $144,000. Hendley & Co. Inc. purchased a new position in shares of AstraZeneca in the fourth quarter worth about $11,373,000. Finally, L & S Advisors Inc acquired a new stake in shares of AstraZeneca during the fourth quarter worth about $14,863,000. Institutional investors and hedge funds own 40.87% of the company’s stock.

AstraZeneca Stock Performance

Shares of OTCMKTS AZNCF opened at $187.10 on Friday. The business’s 50 day moving average price is $187.10 and its 200 day moving average price is $186.01. AstraZeneca PLC has a 52 week low of $122.26 and a 52 week high of $195.00.

AstraZeneca Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.